pyrazines has been researched along with Venous Thromboembolism in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lemon, N; Rech, MA; Sterk, E | 1 |
| Parhofer, KG | 1 |
| Dytfeld, D; Gil, L; Kaźmierczak, M; Komarnicki, M; Nowicki, A; Rupa-Matysek, J; Wojtasińska, E | 1 |
| Vij, R | 1 |
| Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT | 1 |
| Mateos, MV | 1 |
| Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B | 1 |
| Fink, L; Tricot, G; Zangari, M; Zhan, F | 1 |
5 review(s) available for pyrazines and Venous Thromboembolism
| Article | Year |
|---|---|
Topics: Aspirin; Humans; Pyrazines; Randomized Controlled Trials as Topic; Thrombosis; Treatment Outcome; Venous Thromboembolism | 2020 |
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System Diseases; Oligopeptides; Pyrazines; Recurrence; Thalidomide; Venous Thromboembolism | 2011 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism | 2009 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism | 2010 |
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines; Risk; Thalidomide; Venous Thromboembolism | 2011 |
3 other study(ies) available for pyrazines and Venous Thromboembolism
| Article | Year |
|---|---|
Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Benzaldehydes; Hemoglobin, Sickle; Humans; Pyrazines; Pyrazoles; Venous Thromboembolism; Venous Thrombosis | 2022 |
Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation; Platelet Function Tests; Prospective Studies; Pyrazines; Thalidomide; Venous Thromboembolism | 2014 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2011 |